Trending...
- Light Her Way Launches New Cohort of Board of AdviseHERS to Prepare Women for Board-Ready Leadership
- Ashley Wineland To Release Scorching Single and Film Noir Cinematic Video for 'Love Letter'
- Anern Launches the AN-SLZ2 Smart Integrated Solar Street Light
WEXFORD, Pa., Oct. 24, 2024 ~ Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) has recently announced an expansion of its license agreement with Deverra Therapeutics Inc. This move will allow Coeptis to broaden the potential applications of its allogeneic natural killer (NK) cell technology in the treatment of viral infections, pandemic-related illnesses, and emergency stockpiling for future health crises.
The agreement, which was initially secured in August 2023, granted Coeptis exclusive rights to key assets from Deverra including an allogeneic stem cell expansion and directed differentiation platform, two investigational new drug (IND) applications, and two Phase 1 clinical trial stage assets investigating DVX201 as an unmodified NK cell therapy generated from pooled donor CD34+ cells. These assets align with Coeptis' mission to develop treatments for targeting cancer, autoimmune and infectious diseases.
With this revised agreement, Coeptis will now have the ability to expand its field of use in the event of pandemic-related and emergency situations. This includes utilizing unmodified NK cells as a treatment for illnesses and injuries arising from a pandemic or act of terror or war, such as Acute Radiation Sickness (ARS). It also allows for the production and storage of unmodified NK cells in advance to prepare for future health crises.
More on The PennZone
Dave Mehalick, President and CEO of Coeptis Therapeutics expressed his excitement about this expansion stating that it "broadens the applicability of NK cells to ensure that we are prepared for future health crises and potentially address long term side effects that may arise as a result of a pandemic."
Coeptis Therapeutics Holdings, Inc., along with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., is a biopharmaceutical company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Their goal is to disrupt conventional treatment paradigms and improve patient outcomes. The company's product portfolio includes assets licensed from Deverra Therapeutics, an allogeneic cellular immunotherapy platform, and DVX201, a clinical-stage unmodified natural killer cell therapy technology. They are also developing a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR) and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and leading medical researchers at the Karolinska Institutet.
More on The PennZone
Coeptis' business model is centered around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements, co-development relationships, and strategic partnerships. Their focus is on expanding their product rights and offerings, particularly in the areas of cancer and infectious diseases. The company is headquartered in Wexford, PA.
It is important to note that this news release contains forward-looking statements that involve risks and uncertainties. These statements are based on current expectations, forecasts, and assumptions that may cause actual results to differ materially from those projected. Coeptis urges readers to carefully review all cautionary statements regarding these forward-looking statements before making any investment decisions.
For more information on Coeptis Therapeutics Holdings, Inc., please visit their website at https://coeptistx.com/.
The agreement, which was initially secured in August 2023, granted Coeptis exclusive rights to key assets from Deverra including an allogeneic stem cell expansion and directed differentiation platform, two investigational new drug (IND) applications, and two Phase 1 clinical trial stage assets investigating DVX201 as an unmodified NK cell therapy generated from pooled donor CD34+ cells. These assets align with Coeptis' mission to develop treatments for targeting cancer, autoimmune and infectious diseases.
With this revised agreement, Coeptis will now have the ability to expand its field of use in the event of pandemic-related and emergency situations. This includes utilizing unmodified NK cells as a treatment for illnesses and injuries arising from a pandemic or act of terror or war, such as Acute Radiation Sickness (ARS). It also allows for the production and storage of unmodified NK cells in advance to prepare for future health crises.
More on The PennZone
- Safe Health Zones: A Global Breakthrough to Protect Night-Shift Workers from Preventable Harm
- ProfileSpider Launches Powerful One-Click Profile Scraper for Recruiters and Growth Teams
- NATCO Awarded U.S. Patent for Persimonal® – Breakthrough Innovation in Preparing Persimmon Leaf Extract
- Rio Bela Cosmetics Launches Inclusive Line of Organic Skincare Products
- The 7 Visibility Problems Costing Independent Hotels Thousands Every Month
Dave Mehalick, President and CEO of Coeptis Therapeutics expressed his excitement about this expansion stating that it "broadens the applicability of NK cells to ensure that we are prepared for future health crises and potentially address long term side effects that may arise as a result of a pandemic."
Coeptis Therapeutics Holdings, Inc., along with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., is a biopharmaceutical company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Their goal is to disrupt conventional treatment paradigms and improve patient outcomes. The company's product portfolio includes assets licensed from Deverra Therapeutics, an allogeneic cellular immunotherapy platform, and DVX201, a clinical-stage unmodified natural killer cell therapy technology. They are also developing a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR) and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and leading medical researchers at the Karolinska Institutet.
More on The PennZone
- Viola's Babygirl's, LLC Proudly Announces Teri Tobin's Soulful New Christmas EP "Home For The Holidays"
- Stoxtel Introduces High-Throughput "Matrix" Engine to Address Mexico's Crypto Trading Volatility
- Eagles LB Jihaad Campbell Brings Surprise Visit for Together We Dance Foundation
- UK Financial Ltd Sets Listing Date With Catex Exchange For The Listing Of Mayacat The World's First Ever Gold Backed ERC 3643 "SEC Ready" Token
- Cyntexa Announces Updates to ChargeOn on Salesforce AppExchange
Coeptis' business model is centered around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements, co-development relationships, and strategic partnerships. Their focus is on expanding their product rights and offerings, particularly in the areas of cancer and infectious diseases. The company is headquartered in Wexford, PA.
It is important to note that this news release contains forward-looking statements that involve risks and uncertainties. These statements are based on current expectations, forecasts, and assumptions that may cause actual results to differ materially from those projected. Coeptis urges readers to carefully review all cautionary statements regarding these forward-looking statements before making any investment decisions.
For more information on Coeptis Therapeutics Holdings, Inc., please visit their website at https://coeptistx.com/.
Filed Under: Business
0 Comments
Latest on The PennZone
- IDI Consulting Spreads Holiday Cheer to Families in Need with 11th Annual Toys for Tots Drive
- Escajeda Masonry & Concrete Among Pittsburgh's Fastest-Growing Companies
- New 2025–2026 Energy Rebates: Squeaks Services Explains How to Qualify
- CCHR's New Documentary Prescription for Violence Highlights Overlooked Safety Warnings
- Light Her Way Launches New Cohort of Board of AdviseHERS to Prepare Women for Board-Ready Leadership
- Men's Health Network Announces a New Feature to Support the Well-Being of Men When and Where They Are through Text Alerts
- Comp-U-Floor Unveils Powerful New Commercial Module
- Revenue Optics Announces the Appointment of Sonal Chowdhury as Senior Manager – Strategic Operations
- How California Convinces Buyers Not to Purchase New Cars — and How This Hurts Dealers
- Tax Fears and Political Volatility Drive Wealthy UK Residents to Consider Leaving, La Vida Survey Shows
- Titan Steel Buildings Expands Nationwide to Deliver Large Steel Warehouses and Industrial Facilities
- Kaltra Removes Size Barriers for Microchannel Coils with Fully Integrated Large-MCHE Production
- Philadelphia City Council Issues Resolution to Honor Inner Strength Education's 10 Year Anniversary
- Guests Can Save 10 Percent Off New Vacation Rental Homes at KeysCaribbean's Village at Hawks Cay Villas
- Paylode Acquired by Moved to Power the Next Generation of Ancillary Revenue Automation
- Global Preschool Giants Unite to Celebrate the 12th Anniversary of Badanamu's Hit Song "Ponytail"
- America's Leading Annuity Expert Carlton Cap Averil II Joins Tom Hegna on "Financial Freedom with Tom Hegna"
- Cheeron Partners with CRCC to Support Shanghai East Railway Station
- MiBoxer Shines at 2025 Hong Kong International Lighting Fair, Intelligent Lighting Solutions Acclaimed by Global Clients
- Anern Launches the AN-SLZ2 Smart Integrated Solar Street Light